ESRRG promoter hypermethylation as a diagnostic and prognostic biomarker in laryngeal squamous cell carcinoma.
Zhisen ShenYan HuChong-Chang ZhouJie YuanJie XuWenjuan HaoHongxia DengDong YePublished in: Journal of clinical laboratory analysis (2019)
Our study indicated that ESRRG promoter hypermethylation contributed to LSCC-related risks, primarily tumor progression and survival prognosis, in patients. ESRRG promoter methylation could, therefore, be a diagnostic and prognostic biomarker in LSCC.
Keyphrases
- dna methylation
- squamous cell carcinoma
- end stage renal disease
- transcription factor
- gene expression
- newly diagnosed
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- genome wide
- poor prognosis
- prognostic factors
- patient reported outcomes
- human health
- locally advanced
- climate change
- drug induced
- free survival